CRT and Bayer to investigate new approach to gynaecological diseases

Wednesday 25 August 2010

Cancer Research Technology of the UK has signed an agreement with Bayer Schering Pharma AG to evaluate new leptin antagonist peptides as potential treatments for gynaecological diseases, including cancer.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom